Alembic Pharmaceuticals has reported a robust performance for the quarter and financial year ended 31st March, 2026. The company achieved a revenue of INR 18.48 billion, marking a 4% YoY growth. Quarterly profitability was strengthened, with Pre-R&D EBITDA margins improving to 25%, reflecting an 8% year-over-year growth. The company’s reported PAT reached INR 2.03 billion, showcasing a strong 29% growth compared to the same period in the previous year.
Financial Highlights
The company delivered a solid financial performance in Q4 FY26. With total revenue standing at INR 18.48 billion, Alembic maintained steady growth. A significant highlight was the 8% year-over-year increase in Pre-R&D EBITDA, with margins rising to 25%. The reported Net Profit (PAT) reached INR 2.03 billion, representing a notable 29% growth over the prior year, supported by consistent performance across core business segments.
Segment Performance Overview
Performance varied across key divisions during the quarter. The India Branded Business maintained steady momentum with a 4% YoY growth, reporting quarterly revenues of INR 5.68 billion. The US Formulation segment was a key growth driver, recording an 11% year-over-year increase fueled by new product launches and expanded market share. Meanwhile, the API business reported consistent growth of 2%, while the Ex-US Formulation business saw a slight de-growth of 2% due to higher base effects.
Strategic R&D and Market Expansion
Alembic continues to prioritize innovation and long-term pipeline development. R&D spending saw a significant 39% increase, primarily driven by investments in peptide development and increased filing activity. The company’s R&D spend now accounts for 11% of total revenue. Additionally, the company has made strides in its US operations, having launched 15 products in FY26 and establishing a new foothold in the US branded drugs market with the launch of ‘Pivya’ during the quarter.
Sustainability Commitments
Reflecting its commitment to ESG goals, the company has set aggressive sustainability targets, including becoming Net Zero by 2050. Alembic is among the top 10 Indian pharma companies with targets approved by the SBTi. Key achievements include the commissioning of a 24 MW solar park in Vadodara, a 20% reduction in specific water consumption, and the recycling of 81% of its treated water.
Source: BSE
